Live Breaking News & Updates on Announces New Positive Long Term Data

Stay updated with breaking news from Announces new positive long term data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Pegozafermin Shows Sustained Benefit for NASH in Phase 2b Extension Study

Results from the 24-week extension period of the phase 2b ENLIVEN trial showed sustained improvements in liver fat, fibrosis, and inflammation among those treated with 30 mg weekly and 44 mg biweekly pegozafermin. ....

Hank Mansbach , Drug Administration , Breakthrough Therapy , Announces New Positive Long Term Data , Nonalcoholic Steatohepatitis , Granted Breakthrough Therapy Designation , Nonalcoholic Fatty Liver Disease , Phase 2b , Liver Fat , Glp 1 Therapy ,